Plain English Summary
Background and study aims.
A blood vessel abnormality called an aneurysm can cause a bleed within the head. We wish to study the potential benefits of giving a standard cholesterol lowering drug (called Simvastatin) after a bleed has occurred. This is a licensed medication used regularly in the treatment for other vascular conditions including heart attacks and strokes, but it is not licensed at this stage for the treatment of a bleed in the brain. In some instances we may also wish to find out whether the patients genetic makeup can influence the course of your disease, its clinical outcome, or response to the medicine that we are testing.
Who can participate?
Patients aged 18 65years in whom the admitting neurosurgeon has diagnosed a bleed onto the surface of the brain, called a subarachnoid haemorrhage (SAH). We propose to recruit approximately 800 people to the trial.
What does the study involve?
Patients will be allocated randomly (like a flip of the coin) to taking either Simvastatin 40mg or an inactive dummy drug called a placebo. The treatment will be administered as one tablet daily for up to 21 days. If the patient is discharged from the Neurosurgical Unit before 21 days, treatment will be stopped. Nobody (not even the doctors) will know which treatment is being given until the study is over. However, if necessary, the doctor will be able to find out which treatment has been given if any concern arises. Before they leave the hospital we will assess the patients level of recovery. Two short questionnaires will be sent to their home 6 months later asking about their current level of recovery and state of health.
What are the possible benefits and risks of participating?
In the event of taking Simvastatin we hope that this drug might help in recovery. However, this cannot be guaranteed. More likely, the information we obtain from this study may help us to improve on the treatment for future patients suffering from SAH.
Possible rare side effects of Simvastatin include muscle weakness or tenderness, headache, nausea or rash. However no regular side effects have been observed even in patients receiving this treatment for many years. However, in the event of any serious unforeseen reactions, or if any concerns arise, the drug will be stopped immediately.
Where is the study run from?
Department of Neurosurgery, Cambridge University Hospitals NHS Foundation Trust
When is the study starting and how long is it expected to run for?
The study started in May 2006 and is expected to end in January 2014.
Who is funding the study?
British Heart Foundation
Who is the main contact?
Mr Peter J Kirkpatrick
pjk21@medschl.cam.ac.uk
Trial website
Additional identifiers
EudraCT number
2006-000277-30
ClinicalTrials.gov number
NCT00731627
Protocol/serial number
STASH01
Study information
Scientific title
Acronym
STASH
Study hypothesis
Can acute statin therapy reduce the incidence and duration of delayed ischaemic deficits following a subarachnoid haemorrhage (SAH)?
On 04/12/2012 the anticipated end date was changed from 01/05/2009 to 31/01/2014.
Ethics approval
Thames Valley Research Ethics Committee, 06/07/2006, ref: 06/MRE12/26
Study design
Multi-centre double-blind randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
http://www.stashtrial.com/downloads.html
Condition
Subarachnoid haemorrhage
Intervention
Simvastatin versus placebo
Intervention type
Drug
Phase
Phase III
Drug names
Simvastatin
Primary outcome measures
Clinical outcome at six months
Secondary outcome measures
1. Short form questionnaire (SF-36) scores at six months
2. Incidence and duration of delayed ischaemic deficits
3. Need and intensity of delayed ischaemic deficits rescue therapy
4. Incidence of extracranial organ dysfunction and failure
5. Incidence and duration of extracranial organ support
6. Incidence and severity of sepsis
7. Length of intensive care and total acute hospital stay
8. Percentage of patients being discharged directly home
9. Reduction in intensive care requirements for those with sepsis
Overall trial start date
01/05/2006
Overall trial end date
31/01/2014
Reason abandoned
Eligibility
Participant inclusion criteria
1. Patients aged 18-65 years
2. If the admitting neurosurgeon has a high index of suspicion of a spontaneous aneurysmal subarachnoid haemorrhage (good clinical history with convincing computerised tomography [CT] findings)
3. Any clinical grade accepted provided there is a reasonable prospect of survival
4. Delay to randomisation and initiation of trial medication, from the time of the presenting bleed, does not exceed 96 hours
5. Independent prior to the SAH
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
800
Participant exclusion criteria
1. Unsalvageable patients: fixed and dilated pupils after resuscitation, and/or a devastating scan, which precludes definitive therapy
2. Already taking statin therapy
3. Those taking warfarin-type drugs
4. Pregnancy
5. Known renal or hepatic impairment
6. Suspected or known additional disease process, which threatens life expectancy (e.g. malignancy)
7. Known or strong suspicion of drug abuse, alcoholism, or those who are unlikely to be amenable to six-month follow up
Recruitment start date
01/05/2006
Recruitment end date
31/01/2014
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Box 167
Cambridge
CB2 2QQ
United Kingdom
Funders
Funder type
Charity
Funder name
British Heart Foundaton (BHF) (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24837690
Publication citations
-
Results
Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD, , Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial., Lancet Neurol, 2014, 13, 7, 666-675, doi: 10.1016/S1474-4422(14)70084-5.